179 related articles for article (PubMed ID: 34439781)
1. Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2.
Arroyo R; Grant SN; Colombo M; Salvioni L; Corsi F; Truffi M; Ottolina D; Hurst B; Salzberg M; Prosperi D; Kingma PS
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439781
[TBL] [Abstract][Full Text] [Related]
2. A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples.
Madan T; Biswas B; Varghese PM; Subedi R; Pandit H; Idicula-Thomas S; Kundu I; Rooge S; Agarwal R; Tripathi DM; Kaur S; Gupta E; Gupta SK; Kishore U
Am J Respir Cell Mol Biol; 2021 Jul; 65(1):41-53. PubMed ID: 33784482
[TBL] [Abstract][Full Text] [Related]
3. Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles.
Hsieh MH; Beirag N; Murugaiah V; Chou YC; Kuo WS; Kao HF; Madan T; Kishore U; Wang JY
Front Immunol; 2021; 12():641360. PubMed ID: 34054808
[TBL] [Abstract][Full Text] [Related]
4. Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation.
Beirag N; Kumar C; Madan T; Shamji MH; Bulla R; Mitchell D; Murugaiah V; Neto MM; Temperton N; Idicula-Thomas S; Varghese PM; Kishore U
Front Immunol; 2022; 13():960733. PubMed ID: 35967323
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19.
Zhang S; Liu Y; Wang X; Yang L; Li H; Wang Y; Liu M; Zhao X; Xie Y; Yang Y; Zhang S; Fan Z; Dong J; Yuan Z; Ding Z; Zhang Y; Hu L
J Hematol Oncol; 2020 Sep; 13(1):120. PubMed ID: 32887634
[TBL] [Abstract][Full Text] [Related]
6. Malondialdehyde acetaldehyde adduction of surfactant protein D attenuates SARS-CoV-2 spike protein binding and virus neutralization.
Muralidharan A; Bauer C; Katafiasz DM; Pham D; Oyewole OO; Morwitzer MJ; Roy E; Bailey KL; Reid SP; Wyatt TA
Alcohol Clin Exp Res (Hoboken); 2023 Jan; 47(1):95-103. PubMed ID: 36352814
[TBL] [Abstract][Full Text] [Related]
7. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
8. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
9. Recombinant SARS-CoV-2 S Protein Binds to Glycans of the Lactosamine Family in vitro.
Ryzhikov AB; Onkhonova GS; Imatdinov IR; Gavrilova EV; Maksyutov RA; Gordeeva EA; Pazynina GV; Ryzhov IM; Shilova NV; Bovin NV
Biochemistry (Mosc); 2021 Mar; 86(3):243-247. PubMed ID: 33838626
[TBL] [Abstract][Full Text] [Related]
10. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19.
Dakal TC
Immunobiology; 2021 Jan; 226(1):152021. PubMed ID: 33232865
[TBL] [Abstract][Full Text] [Related]
12. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells.
Wang S; Qiu Z; Hou Y; Deng X; Xu W; Zheng T; Wu P; Xie S; Bian W; Zhang C; Sun Z; Liu K; Shan C; Lin A; Jiang S; Xie Y; Zhou Q; Lu L; Huang J; Li X
Cell Res; 2021 Feb; 31(2):126-140. PubMed ID: 33420426
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein.
Zhang S; Go EP; Ding H; Anang S; Kappes JC; Desaire H; Sodroski JG
J Virol; 2022 Feb; 96(3):e0162621. PubMed ID: 34817202
[TBL] [Abstract][Full Text] [Related]
15. The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Κ18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells.
Colunga Biancatelli RML; Solopov PA; Sharlow ER; Lazo JS; Marik PE; Catravas JD
Am J Physiol Lung Cell Mol Physiol; 2021 Aug; 321(2):L477-L484. PubMed ID: 34156871
[TBL] [Abstract][Full Text] [Related]
16. SP-A binding to the SARS-CoV-2 spike protein using hybrid quantum and classical in silico modeling and molecular pruning by Quantum Approximate Optimization Algorithm (QAOA) Based MaxCut with ZDOCK.
Aramyan S; McGregor K; Sandeep S; Haczku A
Front Immunol; 2022; 13():945317. PubMed ID: 36189278
[TBL] [Abstract][Full Text] [Related]
17. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
18. Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity.
Rahman M; Irmler M; Keshavan S; Introna M; Beckers J; Palmberg L; Johanson G; Ganguly K; Upadhyay S
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960806
[TBL] [Abstract][Full Text] [Related]
19. A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody.
Scheim DE
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269703
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells.
Suzuki YJ; Nikolaienko SI; Dibrova VA; Dibrova YV; Vasylyk VM; Novikov MY; Shults NV; Gychka SG
Vascul Pharmacol; 2021 Apr; 137():106823. PubMed ID: 33232769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
